Immatics Management
Management criteria checks 4/4
We currently do not have sufficient information about the CEO.
Key information
Harpreet Singh
Chief executive officer
€3.5m
Total compensation
CEO salary percentage | 14.59% |
CEO tenure | 6yrs |
CEO ownership | 1.3% |
Management average tenure | 5yrs |
Board average tenure | 4.2yrs |
Recent management updates
Recent updates
We Think Immatics (NASDAQ:IMTX) Can Afford To Drive Business Growth
Jun 22Lacklustre Performance Is Driving Immatics N.V.'s (NASDAQ:IMTX) Low P/S
May 17Immatics N.V.: Trading Below Cash, But Not Without Reason
Mar 28Revenues Working Against Immatics N.V.'s (NASDAQ:IMTX) Share Price
Jan 12Immatics N.V.'s (NASDAQ:IMTX) Price Is Out Of Tune With Revenues
Sep 21Immatics (NASDAQ:IMTX) Is In A Good Position To Deliver On Growth Plans
Jul 12Pinning Down Immatics N.V.'s (NASDAQ:IMTX) P/S Is Difficult Right Now
May 03We're Hopeful That Immatics (NASDAQ:IMTX) Will Use Its Cash Wisely
Sep 26We're Hopeful That Immatics (NASDAQ:IMTX) Will Use Its Cash Wisely
Jun 12Immatics launches $110M stock offering
Oct 10Cancer immunotherapy biotech Immatics up 18% on 4x normal volume
Jul 19Here's Why We're Watching Immatics' (NASDAQ:IMTX) Cash Burn Situation
Jan 29Analysts' Revenue Estimates For Immatics N.V. (NASDAQ:IMTX) Are Surging Higher
Dec 16Immatics N.V. (NASDAQ:IMTX) Analysts Are Pretty Bullish On The Stock After Recent Results
Apr 01What Is The Ownership Structure Like For Immatics N.V. (NASDAQ:IMTX)?
Jan 18CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Mar 31 2025 | n/a | n/a | -€22m |
Dec 31 2024 | €4m | €512k | €15m |
Sep 30 2024 | n/a | n/a | -€56m |
Jun 30 2024 | n/a | n/a | -€74m |
Mar 31 2024 | n/a | n/a | -€77m |
Dec 31 2023 | €6m | €488k | -€95m |
Sep 30 2023 | n/a | n/a | -€84m |
Jun 30 2023 | n/a | n/a | -€79m |
Mar 31 2023 | n/a | n/a | -€68m |
Dec 31 2022 | €7m | €522k | €28m |
Compensation vs Market: Harpreet's total compensation ($USD4.07M) is about average for companies of similar size in the US market ($USD3.78M).
Compensation vs Earnings: Harpreet's compensation has been consistent with company performance over the past year.
CEO
Harpreet Singh (50 yo)
Dr. Harpreet Singh, Ph D., has been Non-Executive Director of Immatics N.V. since July 1, 2021 and served as its Supervisory Director since 2021 until July 1, 2021. Dr. Singh serves as Chief Executive Offi...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
CEO, MD | 6yrs | €3.51m | 1.33% $ 9.9m | |
Co-Founder & Chief Innovation Officer | 25.5yrs | no data | 0.33% $ 2.5m | |
Chief Financial Officer | 4.8yrs | no data | 0.23% $ 1.7m | |
Chief Operations Officer | 2.3yrs | no data | 0.31% $ 2.3m | |
General Counsel & Secretary | 5yrs | no data | 0.16% $ 1.2m | |
Chief Development Officer | 5.8yrs | no data | 0.45% $ 3.4m | |
Chief Business Officer & Site Head Munich | no data | no data | 0.35% $ 2.6m | |
Chief Medical Officer | 5.1yrs | no data | 0.28% $ 2.1m | |
Head of Strategy | no data | no data | 0.23% $ 1.7m | |
Co-Founder & Member of the Scientific Advisory Board | 25.5yrs | no data | no data | |
Vice President of SEC Reporting & Accounting | 1.5yrs | no data | no data | |
Vice President of Marketing | 1.5yrs | no data | no data |
Experienced Management: IMTX's management team is seasoned and experienced (5 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
CEO, MD | 4yrs | €3.51m | 1.33% $ 9.9m | |
Co-Founder & Member of the Scientific Advisory Board | no data | no data | no data | |
Independent Non-Executive Director | 4yrs | €353.00k | 0.072% $ 534.5k | |
Non-Executive Chairman | 4yrs | €370.00k | 0.33% $ 2.5m | |
Independent Vice Chair of the Board of Directors | 4yrs | €333.00k | 0.072% $ 534.5k | |
Member of Scientific Advisory Board | 5.1yrs | no data | no data | |
Co-Chair of the Scientific Advisory Board | 4.3yrs | no data | no data | |
Independent Non-Executive Director | 4yrs | €348.00k | 0.072% $ 534.5k | |
Member of Scientific Advisory Board | no data | no data | no data | |
Member of Scientific Advisory Board | 5.5yrs | no data | no data | |
Co-Chair of the Scientific Advisory Board | 4.8yrs | no data | no data | |
Member of Scientific Advisory Board | 5yrs | no data | no data |
Experienced Board: IMTX's board of directors are considered experienced (4.2 years average tenure).
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/07/17 22:12 |
End of Day Share Price | 2025/07/17 00:00 |
Earnings | 2025/03/31 |
Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Immatics N.V. is covered by 9 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Alec Stranahan | BofA Global Research |
Eric Schmidt | Cantor Fitzgerald & Co. |
Yevgeniya Livshits | Chardan Capital Markets, LLC |